AU2002236587A1 - Compositions for adhesion prevention - Google Patents

Compositions for adhesion prevention

Info

Publication number
AU2002236587A1
AU2002236587A1 AU2002236587A AU3658702A AU2002236587A1 AU 2002236587 A1 AU2002236587 A1 AU 2002236587A1 AU 2002236587 A AU2002236587 A AU 2002236587A AU 3658702 A AU3658702 A AU 3658702A AU 2002236587 A1 AU2002236587 A1 AU 2002236587A1
Authority
AU
Australia
Prior art keywords
compositions
adhesion prevention
administration
formulations
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002236587A
Inventor
Michael P. Diamond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002236587A1 publication Critical patent/AU2002236587A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sealing Material Composition (AREA)
  • Macromonomer-Based Addition Polymer (AREA)

Abstract

Compositions and methods for the prevention of adhesion development involve the administration of therapeutic formulations of a halogenated organic compound to a patient in need of treatment. The formulations can include suitable carriers for optimal administration.
AU2002236587A 2000-11-21 2001-11-16 Compositions for adhesion prevention Abandoned AU2002236587A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25229700P 2000-11-21 2000-11-21
US60/252,297 2000-11-21
PCT/US2001/047362 WO2002041841A2 (en) 2000-11-21 2001-11-16 Compositions for adhesion prevention

Publications (1)

Publication Number Publication Date
AU2002236587A1 true AU2002236587A1 (en) 2002-06-03

Family

ID=22955426

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002236587A Abandoned AU2002236587A1 (en) 2000-11-21 2001-11-16 Compositions for adhesion prevention

Country Status (7)

Country Link
US (1) US6518308B2 (en)
EP (1) EP1347754B1 (en)
AT (1) ATE371446T1 (en)
AU (1) AU2002236587A1 (en)
CA (1) CA2429624A1 (en)
DE (1) DE60130253D1 (en)
WO (1) WO2002041841A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758654B2 (en) * 2004-05-20 2010-07-20 Kensey Nash Corporation Anti-adhesion device
EP1915169A2 (en) * 2005-07-12 2008-04-30 Renovo Limited Pharmaceutical compositions comprising a tgf-beta superfamily member
US20090269390A1 (en) * 2008-04-25 2009-10-29 Medtronic, Inc. Medical devices, polymers, compositions, and methods for delivering a haloacetate
AU2010229042A1 (en) * 2009-03-23 2011-11-10 Kross-Link Laboratories Method for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition prepared on-site

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456346B (en) 1984-07-23 1988-09-26 Pharmacia Ab GEL TO PREVENT ADHESION BETWEEN BODY TISSUE AND SET FOR ITS PREPARATION
US4819617A (en) 1986-09-04 1989-04-11 University Of Florida Viscoelastic material for ophthalmic surgery
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
EP0840623B1 (en) 1995-07-21 2007-07-18 Brown University Research Foundation Compositions for gene therapy comprising nucleic acid loaded polymeric microparticles
US6011017A (en) * 1998-04-15 2000-01-04 Cypros Pharmaceutical Corp. Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass
CA2354863A1 (en) 1998-10-02 2000-04-13 University Of Florida Prevention of adhesions
US6211217B1 (en) * 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US6579889B2 (en) * 2000-06-22 2003-06-17 Merck & Co., Inc. Substituted isonipecotyl derivatives as inhibitors of cell adhesion

Also Published As

Publication number Publication date
WO2002041841A3 (en) 2002-10-31
EP1347754A2 (en) 2003-10-01
US6518308B2 (en) 2003-02-11
EP1347754B1 (en) 2007-08-29
WO2002041841A2 (en) 2002-05-30
US20020068762A1 (en) 2002-06-06
DE60130253D1 (en) 2007-10-11
EP1347754A4 (en) 2004-10-13
ATE371446T1 (en) 2007-09-15
CA2429624A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
AU7031500A (en) Therapeutic quinazoline compounds
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
NZ514574A (en) Novel method of treatment
AU5986200A (en) Compounds
AU2623201A (en) Controlled delivery of therapeutic agents by insertable medical devices
AU6825300A (en) Compounds
HK1064921A1 (en) Sustained release formulations of oxymorphone
AU1200501A (en) Drug delivery catheters that attach to tissue and methods for their use
AU2274201A (en) Compounds and compositions for delivering active agents
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
AU3850600A (en) Dalda analogs and their use
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
AU1262501A (en) Compositions for transdermal and transmucosal administration of therapeutic agents
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
IL143985A0 (en) New use of melagatran
CA2417935A1 (en) Anti-inflammatory medicament
GB9907571D0 (en) Compounds
AU2003290015A1 (en) Mastitis treatment
AU2420001A (en) Methods and compositions for the treatment of pain
AU2002236587A1 (en) Compositions for adhesion prevention
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
MXPA01012936A (en) Pharmaceutical composition containing sibutramine and orlistat.